REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 222 filers reported holding REATA PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.22 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $1,402,664 | +15.6% | 13,757 | +3.1% | 0.01% | +12.5% |
Q1 2023 | $1,213,236 | +144.2% | 13,344 | +2.0% | 0.01% | +166.7% |
Q4 2022 | $496,871 | +50.6% | 13,079 | -0.4% | 0.00% | +50.0% |
Q3 2022 | $330,000 | -16.0% | 13,126 | +1.4% | 0.00% | -33.3% |
Q2 2022 | $393,000 | -12.1% | 12,941 | -5.1% | 0.00% | +50.0% |
Q1 2022 | $447,000 | +16.1% | 13,631 | -6.6% | 0.00% | 0.0% |
Q4 2021 | $385,000 | -74.5% | 14,590 | -2.9% | 0.00% | -75.0% |
Q3 2021 | $1,512,000 | -30.5% | 15,027 | -2.3% | 0.01% | +14.3% |
Q2 2021 | $2,177,000 | +3787.5% | 15,384 | +2657.0% | 0.01% | – |
Q1 2021 | $56,000 | -21.1% | 558 | -2.6% | 0.00% | – |
Q4 2020 | $71,000 | +22.4% | 573 | -3.9% | 0.00% | – |
Q3 2020 | $58,000 | -39.6% | 596 | -2.8% | 0.00% | – |
Q2 2020 | $96,000 | -95.0% | 613 | -95.4% | 0.00% | -100.0% |
Q1 2020 | $1,936,000 | -32.4% | 13,414 | -4.2% | 0.01% | 0.0% |
Q4 2019 | $2,863,000 | +181.0% | 14,005 | +10.3% | 0.01% | +175.0% |
Q3 2019 | $1,019,000 | -15.5% | 12,694 | -0.7% | 0.00% | -20.0% |
Q2 2019 | $1,206,000 | +17.1% | 12,782 | +6.1% | 0.01% | +25.0% |
Q1 2019 | $1,030,000 | +49.1% | 12,052 | -2.1% | 0.00% | +33.3% |
Q4 2018 | $691,000 | -31.9% | 12,310 | -0.8% | 0.00% | 0.0% |
Q3 2018 | $1,014,000 | +180.1% | 12,404 | +19.7% | 0.00% | +200.0% |
Q2 2018 | $362,000 | +144.6% | 10,360 | +43.3% | 0.00% | 0.0% |
Q1 2018 | $148,000 | -31.5% | 7,232 | -5.1% | 0.00% | 0.0% |
Q4 2017 | $216,000 | -7.7% | 7,622 | +1.2% | 0.00% | 0.0% |
Q3 2017 | $234,000 | +40.1% | 7,528 | +42.5% | 0.00% | 0.0% |
Q2 2017 | $167,000 | +108.8% | 5,281 | +49.6% | 0.00% | – |
Q1 2017 | $80,000 | +12.7% | 3,530 | +8.0% | 0.00% | – |
Q4 2016 | $71,000 | -99.9% | 3,270 | -0.3% | 0.00% | – |
Q3 2016 | $86,434,000 | +33.7% | 3,279 | +0.2% | 0.00% | – |
Q2 2016 | $64,662,000 | – | 3,274 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CPMG Inc | 2,896,901 | $288,821,000 | 55.24% |
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 100,000 | $9,970,000 | 15.20% |
Tolleson Wealth Management, Inc. | 108,000 | $10,768,000 | 3.25% |
MADDEN SECURITIES Corp | 34,787 | $3,468,000 | 2.03% |
Biondo Investment Advisors, LLC | 101,204 | $10,090,000 | 2.01% |
LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,027,000 | 1.91% |
Duquesne Family Office | 749,897 | $74,765,000 | 1.65% |
Sofinnova Investments, Inc. | 238,520 | $23,780,000 | 1.43% |
Camber Capital Management LP | 400,000 | $39,880,000 | 1.37% |
Integral Health Asset Management, LLC | 44,000 | $4,387,000 | 1.25% |